| Kylie Sharon Gale, | |
|
112 Market St, Lynn, MA 01901-1148 | |
| (781) 592-5691 | |
| Not Available |
| Full Name | Kylie Sharon Gale |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 112 Market St, Lynn, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023716800 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kylie Sharon Gale, 110 Boston St, Salem, MA 01970-1402 Ph: () - | Kylie Sharon Gale, 112 Market St, Lynn, MA 01901-1148 Ph: (781) 592-5691 |
News Archive
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Though the number of people in Zimbabwe in need of food aid has dropped from seven million in 2002-2003 to one million currently, the number could still rise by 600,000 in 2013, IRIN reports in an analysis of the humanitarian and political situation in the country.
Array BioPharma Inc. today announced the commencement of a drug discovery collaboration with Takeda Chemical Industries, Ltd. to create a series of small molecule drug leads against a Takeda target. This collaboration is in addition to Array's existing research agreement with Takeda that began in 2001.
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
› Verified 6 days ago
Mr. Daniel Bistransin, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 95 Pleasant St, Lynn, MA 19102 Phone: 781-596-9222 | |
Ms. Carmen N. Amador, MSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 Market St, Lynn, MA 01901 Phone: 781-715-5857 | |
Emily Rennard, Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 Market St, Lynn, MA 01901 Phone: 781-691-7665 | |
Kristen Congelosi, Counselor Medicare: Not Enrolled in Medicare Practice Location: 11 Circle Ave, Lynn, MA 01905 Phone: 978-675-7801 | |
Tyla Rodriguez, Counselor Medicare: Not Enrolled in Medicare Practice Location: 95 Pleasant St, Lynn, MA 01901 Phone: 781-715-2302 | |
Sarah Elizabeth Thompson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 95 Pleasant St, Lynn, MA 01901 Phone: 781-581-4444 | |
Carolyna Mercado, Counselor Medicare: Not Enrolled in Medicare Practice Location: 181 Union St, Suite J, Lynn, MA 01901 Phone: 781-244-1950 |